Deborah Mistal, DO
Family Medicine · Drums, PANPI 1033280417
Payments from drug & device makers
Across 161 payments — averaging $23.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$751
- Novo Nordisk$668
- AstraZeneca$418
- Boehringer Ingelheim$228
- Lilly USA, LLC$195
- GSK$151
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,74199%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 21 | $751 |
| Novo Nordisk | 38 | $668 |
| AstraZeneca | 18 | $418 |
| Boehringer Ingelheim | 11 | $228 |
| Lilly USA, LLC | 7 | $195 |
| GSK | 10 | $151 |
| Alkermes, Inc. | 3 | $138 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $125 |
| AbbVie | 1 | $125 |
| Actelion Pharmaceuticals US, Inc. | 1 | $122 |
| Amgen | 8 | $118 |
| Phathom Pharmaceuticals, Inc. | 1 | $99 |
| Pfizer | 6 | $83 |
| Astellas Pharma US Inc | 4 | $83 |
| Merck | 6 | $77 |
| Johnson & Johnson | 1 | $67 |
| Mylan Specialty L.p. | 5 | $67 |
| E.r. Squibb & Sons, L.L.C. | 3 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $41 |
| Novartis | 3 | $39 |
| Radius Health, Inc. | 2 | $30 |
| Shire North American Group Inc | 2 | $26 |
| Sunovion Pharmaceuticals Inc. | 2 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Indivior Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,795 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 61 | $85,410 |
| EliquisApixaban | 33 | $53,146 |
| OzempicSemaglutide | 55 | $50,875 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $42,726 |
| TrulicityDulaglutide | 16 | $32,640 |
| MyrbetriqMirabegron | 55 | $31,266 |
| Nurtec OdtRimegepant Sulfate | 22 | $23,562 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $21,636 |
| FarxigaDapagliflozin Propanediol | 24 | $20,418 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $19,909 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 108 | $18,186 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $15,733 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $10,597 |
| TradjentaLinagliptin | 17 | $8,678 |
| OxycontinOxycodone Hcl | 13 | $6,860 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta | $228 | $104,68698 claims |
| PfizerEliquis, Nurtec Odt | $83 | $76,70755 claims |
| Novo NordiskOzempic | $668 | $50,87555 claims |
| GSKTrelegy Ellipta | $151 | $42,72624 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $418 | $42,05359 claims |
| Lilly USA, LLCTrulicity | $195 | $32,64016 claims |
| Astellas Pharma US IncMyrbetriq | $83 | $31,26655 claims |
| Indivior Inc.Suboxone | $14 | $3,55012 claims |
| AbbVieSynthroid | $125 | $2,50932 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Drums
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.